DAX Ends Flat at 17770.02 — Data Talk
The DAX is up 3.79 points or 0.02% today to 17770.02
--Up two of the past three trading days
--Off 3.91% from its record close of 18492.49 hit Thursday, March 28, 2024
--Off 3.91% from its 52-week high of 18492.49 hit Thursday, March 28, 2024
--Up 20.99% from its 52-week low of 14687.41 hit Friday, Oct. 27, 2023
--Rose 11.79% from 52 weeks ago
--Off 3.91% from its 2024 closing high of 18492.49 hit Thursday, March 28, 2024
--Up 8.14% from its 2024 closing low of 16431.69 hit Wednesday, Jan. 17, 2024
--Month-to-date it is down 3.91%
--Year-to-date it is up 1018.38 points or 6.08%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 17, 2024 12:38 ET (16:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track